![Flowchart for the ESGO/ESTRO/ESP 2020 endometrial carcinoma guidelines | International Journal of Gynecologic Cancer Flowchart for the ESGO/ESTRO/ESP 2020 endometrial carcinoma guidelines | International Journal of Gynecologic Cancer](https://ijgc.bmj.com/content/ijgc/31/9/1313/F1.large.jpg)
Flowchart for the ESGO/ESTRO/ESP 2020 endometrial carcinoma guidelines | International Journal of Gynecologic Cancer
![Increased risk of secondary bladder cancer after radiation therapy for endometrial cancer | Scientific Reports Increased risk of secondary bladder cancer after radiation therapy for endometrial cancer | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-022-05126-w/MediaObjects/41598_2022_5126_Fig1_HTML.png)
Increased risk of secondary bladder cancer after radiation therapy for endometrial cancer | Scientific Reports
![Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆ - Annals of Oncology Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆ - Annals of Oncology](https://www.annalsofoncology.org/cms/asset/d128df76-ee8d-4434-9672-ba832c26bb7e/gr3.jpg)
Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆ - Annals of Oncology
![Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial - The Lancet Oncology Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/8d8bf3a6-fe30-49f1-8ced-922c620e132a/gr1.gif)
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial - The Lancet Oncology
![Socioeconomic inequality and omission of adjuvant radiation therapy in high-risk, early-stage endometrial cancer - Gynecologic Oncology Socioeconomic inequality and omission of adjuvant radiation therapy in high-risk, early-stage endometrial cancer - Gynecologic Oncology](https://www.gynecologiconcology-online.net/cms/asset/a31d50db-3699-4490-bc1b-f2487d48e267/gr1.jpg)
Socioeconomic inequality and omission of adjuvant radiation therapy in high-risk, early-stage endometrial cancer - Gynecologic Oncology
![Radiation Therapy for Endometrial Cancer: An American Society for Radiation Oncology Clinical Practice Guideline - Practical Radiation Oncology Radiation Therapy for Endometrial Cancer: An American Society for Radiation Oncology Clinical Practice Guideline - Practical Radiation Oncology](https://www.practicalradonc.org/cms/asset/f3f79607-5136-4ee4-ba98-ac1f31680041/gr2.jpg)
Radiation Therapy for Endometrial Cancer: An American Society for Radiation Oncology Clinical Practice Guideline - Practical Radiation Oncology
![Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial - The Lancet Oncology Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/d1f68703-74b8-4712-ab0a-a260f476e76a/gr1.gif)
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial - The Lancet Oncology
![Treatment of Early Stage High-Risk Endometrioid-Type Endometrial Cancer and Patterns of Disease Relapse: A Retrospective Analysis - Advances in Radiation Oncology Treatment of Early Stage High-Risk Endometrioid-Type Endometrial Cancer and Patterns of Disease Relapse: A Retrospective Analysis - Advances in Radiation Oncology](https://advancesradonc.com/cms/asset/1151d1e3-41d9-4464-b2d6-8d6874a3e278/gr1.jpg)
Treatment of Early Stage High-Risk Endometrioid-Type Endometrial Cancer and Patterns of Disease Relapse: A Retrospective Analysis - Advances in Radiation Oncology
![Systemic review: Radiation therapy alone in medical non-operable endometrial carcinoma - ScienceDirect Systemic review: Radiation therapy alone in medical non-operable endometrial carcinoma - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0959804916323073-gr1.jpg)
Systemic review: Radiation therapy alone in medical non-operable endometrial carcinoma - ScienceDirect
![IJERPH | Free Full-Text | Predictors of Survival in Women with High-Risk Endometrial Cancer and Comparisons of Sandwich versus Concurrent Adjuvant Chemotherapy and Radiotherapy IJERPH | Free Full-Text | Predictors of Survival in Women with High-Risk Endometrial Cancer and Comparisons of Sandwich versus Concurrent Adjuvant Chemotherapy and Radiotherapy](https://www.mdpi.com/ijerph/ijerph-17-05941/article_deploy/html/images/ijerph-17-05941-g001.png)
IJERPH | Free Full-Text | Predictors of Survival in Women with High-Risk Endometrial Cancer and Comparisons of Sandwich versus Concurrent Adjuvant Chemotherapy and Radiotherapy
![Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Semantic Scholar Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/f777f7bb7385caf01110f059199c9244710975dd/3-Table3-1.png)
Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Semantic Scholar
![Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial - ScienceDirect Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0090825818310849-gr1a.jpg)
Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial - ScienceDirect
![Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology in: Journal of the National Comprehensive Cancer Network Volume 16 Issue 2 (2018) Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology in: Journal of the National Comprehensive Cancer Network Volume 16 Issue 2 (2018)](https://jnccn.org/view/journals/jnccn/16/2/0170fig02.jpeg)
Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology in: Journal of the National Comprehensive Cancer Network Volume 16 Issue 2 (2018)
![Cancers | Free Full-Text | Endometrial Cancer Molecular Characterization: The Key to Identifying High-Risk Patients and Defining Guidelines for Clinical Decision-Making? Cancers | Free Full-Text | Endometrial Cancer Molecular Characterization: The Key to Identifying High-Risk Patients and Defining Guidelines for Clinical Decision-Making?](https://www.mdpi.com/cancers/cancers-13-03988/article_deploy/html/images/cancers-13-03988-g001.png)
Cancers | Free Full-Text | Endometrial Cancer Molecular Characterization: The Key to Identifying High-Risk Patients and Defining Guidelines for Clinical Decision-Making?
![Prognosis and adjuvant chemotherapy for patients with positive peritoneal cytology in stage IA endometrial cancer | Scientific Reports Prognosis and adjuvant chemotherapy for patients with positive peritoneal cytology in stage IA endometrial cancer | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-021-03975-5/MediaObjects/41598_2021_3975_Fig1_HTML.png)